Addeo Raffaele, Lamberti Giuseppe, Simonetti Giorgia, Iodice Patrizia, Marinelli Alfredo, Montella Liliana, Cappabianca Salvatore, Gaviani Paola, Caraglia Michele, Prete Salvatore Del, Silvani Antonio
Medical Oncology Unit, 'San Giovanni di Dio' Hospital, A.S.L. Napoli 2 Nord, Frattamaggiore (Naples), Italy.
Department of Experimental, Diagnostic & Specialty Medicine, S.Orsola-Malpighi University Hospital, Bologna, Italy.
CNS Oncol. 2019 Jun 1;8(2):CNS32. doi: 10.2217/cns-2019-0004. Epub 2019 Jul 10.
To assess the efficacy and safety of alternative fotemustine administration schedule in elderly patients with recurrent glioblastoma. Patients aged >65 years with recurrent glioblastoma received fotemustine (80 mg/m; days 1, 15, 30, 45 and 60, and subsequently every 4 weeks). Primary end point was progression-free survival (PFS) rate at 6 months. Main secondary end point was safety. 58 patients were enrolled at two centers. PFS at 6 months was 47% (27 patients) and overall response rate was 29%. Median PFS and survival were 6 and 7 months, respectively, and longer in responders versus nonresponders. No grade 3-4 hematological toxicities occurred. The alternative fotemustine administration schedule was an effective and safe treatment for recurrent glioblastoma in elderly patients.
评估替莫唑胺替代给药方案治疗老年复发性胶质母细胞瘤患者的疗效和安全性。年龄>65岁的复发性胶质母细胞瘤患者接受替莫唑胺（80mg/m²；第1、15、30、45和60天给药，随后每4周给药一次）。主要终点是6个月时的无进展生存率（PFS）。主要次要终点是安全性。两个中心共纳入58例患者。6个月时的PFS为47%（27例患者），总缓解率为29%。PFS和总生存期的中位数分别为6个月和7个月，缓解者较未缓解者更长。未发生3-4级血液学毒性。替莫唑胺替代给药方案是治疗老年复发性胶质母细胞瘤患者的一种有效且安全的治疗方法。
